Longevity Biotech Fellowship puts Thalion Initiative in the spotlight as a "CERN for aging biology" project: the organization wants to build shared assays, datasets, and tools before commercialization
Longevity Biotech Fellowship puts Thalion Initiative in the spotlight as a "CERN for aging biology" project: the organization wants to build shared assays, datasets, and tools before commercialization
On April 28, Nathan Cheng announced a conversation with Todd White, Managing Director of The Thalion Initiative. The event will take place on May 5 through Longevity Biotech Fellowship; the Luma page already shows 142 participants. The focus is a philanthropic research organization operating upstream of venture-backed startups and pharma.
On the event page, Thalion is described with unusual bluntness: an attempt to build a "CERN for aging biology." Here, CERN means large-scale shared scientific infrastructure: a place where different groups can access instruments, standards, and data that are too expensive or too slow for any single company to build alone.
"Todd White is building what he calls a CERN for aging biology: a philanthropic, precommercial research organization that standardizes assays, datasets, and infrastructure that no single biotech company can justify to its shareholders."
That is a strong framing, but for now it remains the framing of the event itself. Thalion already has a website, a team, and a scientific advisory board, while the May 5 conversation is still just an announcement. What matters here is the model LBF is choosing to spotlight: bringing precommercial infrastructure into public view for people building careers and companies around radical life extension.
On the Thalion website, the problem is framed in terms of biology's lack of predictability. The organization argues that drug development often stalls because the models are weak: biologists measure a great deal, but still struggle to predict what an intervention will do in a living system. Their answer is comparative biology of long-lived animals, synthetic biology, embryonic rejuvenation, new measurement tools, and open datasets.
In this context, comparative biology means looking for mechanisms in species that already do what humans want to achieve technologically. Thalion points to elephants with low cancer risk, Greenland whales with long lifespans, and axolotls with regenerative capacity. The idea is straightforward: nature has already tested some of these solutions across millions of years of evolution, while aging labs have rarely studied them systematically.
This aligns well with what Norn Group called a shortage of open data for AI in longevity: models need long records of how tissues, organs, and whole organisms change after interventions. Thalion speaks in similar terms, but puts shared assays, measurement tools, biobanks, and models alongside the data as common resources that should be useful to many labs and companies.
There is also a policy layer. On April 24, European aging researchers, through EFAR, acknowledged that Europe has no dedicated funding mechanism for healthy aging. Thalion offers a different answer to the same gap: early-stage infrastructure can be housed inside a philanthropic organization. Pharma and venture funds usually want an asset, a patent, and a path to market; Thalion is trying to push on the stage before the asset exists, where the field still needs better measurements, models, and questions so the next asset is not built on guesswork again.
The project's scientific network already looks heavyweight. Thalion lists Vera Gorbunova, Andrei Seluanov, Vadim Gladyshev, Emma Teeling, Steve Austad, David Gems, Michael Levin, and Peter Fedichev across its team and advisory bodies. Todd White also appears on the author list of the roadmap of 100 open questions in biogerontology.
The weak point is already visible: Thalion speaks the language of very big science. "CERN," "Manhattan Project," and "cheat codes for human longevity" can easily turn into branding without measurable outputs. The real test will be concrete: which datasets get opened, which assays are standardized, which models become better at predicting experiments, and which outside labs begin using them.